ID: ALA5268942

Max Phase: Preclinical

Molecular Formula: C18H16N2O4

Molecular Weight: 324.34

Associated Items:

Representations

Canonical SMILES:  COc1cccc2c(=O)c(C(=O)Nc3cc(O)ccc3C)c[nH]c12

Standard InChI:  InChI=1S/C18H16N2O4/c1-10-6-7-11(21)8-14(10)20-18(23)13-9-19-16-12(17(13)22)4-3-5-15(16)24-2/h3-9,21H,1-2H3,(H,19,22)(H,20,23)

Standard InChI Key:  IMJLIRUSQUAOEG-UHFFFAOYSA-N

Associated Targets(non-human)

PC-12 7051 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 324.34Molecular Weight (Monoisotopic): 324.1110AlogP: 2.80#Rotatable Bonds: 3
Polar Surface Area: 91.42Molecular Species: NEUTRALHBA: 4HBD: 3
#RO5 Violations: 0HBA (Lipinski): 6HBD (Lipinski): 3#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.16CX Basic pKa: CX LogP: 3.02CX LogD: 3.02
Aromatic Rings: 3Heavy Atoms: 24QED Weighted: 0.69Np Likeness Score: -0.59

References

1. Chen X, Zhu H, Liu X, Li Q, Dong M..  (2023)  Design and synthesis of novel GluN2A NMDAR positive allosteric modulators via scaffold hopping strategy as anti-stroke therapeutic agents.,  83  [PMID:36934527] [10.1016/j.bmc.2023.117236]

Source